BB Biotech AG operates in the Investors sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BB Biotech AG with three other
financial institutions in Europe:
Blue Cap AG
sales of 258.91 million Euros [US$313.44 million]
of which 39%
was Plastics Technology),
Aforti Holding SA
(1.01 billion Polish New Zlotys [US$271.83 million]
HBM Healthcare Investments AG
(235.06 million Swiss Francs [US$261.76 million]
Sales were up sharply during the first
quarter of 2021 versus the previous year's first quarter.
During the first
quarter of 2021, sales at BB Biotech AG totalled
29.27 million Swiss Francs.
an increase of 500.8%
from the 4.87 million Swiss Francs in sales at the company during the first quarter of 2020.
BB Biotech AG reported sales of 280.93 million Swiss Francs (US$312.84 million)
December of 2020.
increase of 16.6%
versus 2019, when the company's sales were 240.87 million Swiss Francs.
The sales level in 2020 was fairly close to the level five years ago: in 2015, BB Biotech AG had sales
of 292.00 million Swiss Francs.